Marshall Wace North America’s Ligand Pharmaceuticals LGND Stock Holding History

Marshall Wace North America’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-51,833	Closed	-$3.22M	–	1452
2019 Q3	$3.22M	Sell	51,833 -18,167	-26%	-$1.14M	0.02%	444
2019 Q2	$4.99M	Sell	70,000 -43,901	-39%	-$3.23M	0.03%	363
2019 Q1	$8.93M	Buy	113,901 +95,539	+520%	+$7.24M	0.06%	223
2018 Q4	$1.55M	Buy	+18,362	New	+$1.96M	0.02%	495
2017 Q4	–	Sell	-3,498	Closed	-$297K	–	1502
2017 Q3	$297K	Buy	+3,498	New	+$277K	﹤0.01%	1136
2013 Q4	$2.14M	Buy	65,253 +59,873	+1,113%	+$1.95M	0.05%	285
2013 Q3	$145K	Buy	+5,380	New	+$151K	﹤0.01%	572

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Marshall Wace North America's LGND Position: Q4 2019 in Review

Marshall Wace North America sold out of Ligand Pharmaceuticals (LGND) in Q4 2019, closing a stake of 51,833 shares — an estimated $3.22M sold.

Marshall Wace North America first reported a position in LGND in Q3 2013 and held it in 7 quarters. The position peaked at $8.93M in Q1 2019. 266 funds tracked by Wall St. Rank hold LGND as of Q4 2019.

Marshall Wace North America reported no remaining Ligand Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Marshall Wace North America sold 51,833 Ligand Pharmaceuticals shares in Q4 2019, an estimated $3.22M.
Marshall Wace North America first reported a position in Ligand Pharmaceuticals in Q3 2013 and held it in 7 quarters.
Marshall Wace North America's Ligand Pharmaceuticals position peaked at $8.93M in Q1 2019.
266 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2019.

Based on Marshall Wace North America's 13F filing for Q4 2019, filed 14 Feb 2020.